Nadofaragene firadenovec - FKD Therapies

Drug Profile

Nadofaragene firadenovec - FKD Therapies

Alternative Names: Instiladrin; Nadofaragene firadenovec/Syn3; rAd-IFN; rAd-IFN/Syn3; SCH-721015

Latest Information Update: 09 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer FKD Therapies
  • Class Antineoplastics; IFNA2B gene therapies
  • Mechanism of Action Gene transference; IFNA2B expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Bladder cancer

Most Recent Events

  • 03 May 2018 Nadofaragene firadenovec sub-licensed to Ferring Pharmaceuticals worldwide by FKD Therapies for the treatment of Bladder cancer
  • 03 May 2018 Nadofaragene firadenovec - FKD Therapies receives Breakthrough Therapy status for Bladder cancer in USA
  • 03 May 2018 Nadofaragene firadenovec - FKD Therapies receives Fast Track designation for Bladder cancer [Intravesicular,Infusion] (Late-stage disease, Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top